Research ExplorerPublicationsExtent of lymph node dissection and recurrence-free survival...

Extent of lymph node dissection and recurrence-free survival after radical cystectomy

Standard

Extent of lymph node dissection and recurrence-free survival after radical cystectomy : a meta-analysis. / Mandel, Philipp; Tilki, Derya; Eslick, Guy D.

In: UROL ONCOL-SEMIN ORI, Vol. 32, No. 8, 11.2014, p. 1184-90.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mandel, P, Tilki, D & Eslick, GD 2014, 'Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis', UROL ONCOL-SEMIN ORI, vol. 32, no. 8, pp. 1184-90. https://doi.org/10.1016/j.urolonc.2014.01.017

APA

Mandel, P., Tilki, D., & Eslick, G. D. (2014). Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis. UROL ONCOL-SEMIN ORI, 32(8), 1184-90. https://doi.org/10.1016/j.urolonc.2014.01.017

Vancouver

Mandel P, Tilki D, Eslick GD. Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis. UROL ONCOL-SEMIN ORI. 2014 Nov;32(8):1184-90. https://doi.org/10.1016/j.urolonc.2014.01.017

Bibtex

@article{057ae6c053f04d168dd44fb8dd8f730f,
title = "Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis",
abstract = "INTRODUCTION: Lymph node dissection (LND) at the time of radical cystectomy (RC) is the standard of care in the treatment of muscle-invasive bladder cancer. However, no final consensus about its optimal extent has been reached.METHODS: We conducted a meta-analysis to determine the effect of the extent of LND on 5-year recurrence-free survival and its complication rates in patients undergoing RC. A systematic search of MEDLINE, PubMed, and EMBASE has been performed. All studies published until June 2013 and providing information on 5-year recurrence-free survival were included in the analysis.RESULTS: We analyzed the recurrence-free survival data of 11 studies on standard or extended LND or both in patients undergoing RC. The extended (above the bifurcation of iliac vessels) LND showed a significant trend toward a higher proportion of lymph node-positive patients (odds ratio = 1.39; 95% CI: 0.96-2.00; P = 0.08). Including all studies that compare extended with standard LND, the overall odds ratio for the 5-year recurrence-free survival is 1.63 (95% CI: 1.28-2.07, P<0.001), showing a strong and statistical significant survival benefit for the group of patients who underwent extended LND. Moreover, the weighted average 5-year recurrence-free survival rate of all existing studies on standard LND is significantly different from the ones reporting extended LND rates. No differences in perioperative mortality or complication rates were reported.CONCLUSION: The present meta-analysis provides evidence to the positive effect of extended LND on recurrence-free survival and its diagnostic benefit in patients undergoing RC. Patients who underwent extended LND did not suffer from higher complication rates or perioperative mortality.",
keywords = "Cystectomy, Disease-Free Survival, Humans, Lymph Node Excision, Lymph Nodes, Prognosis, Treatment Outcome, Urinary Bladder Neoplasms, Journal Article, Meta-Analysis",
author = "Philipp Mandel and Derya Tilki and Eslick, {Guy D}",
note = "Copyright {\textcopyright} 2014 Elsevier Inc. All rights reserved.",
year = "2014",
month = nov,
doi = "10.1016/j.urolonc.2014.01.017",
language = "English",
volume = "32",
pages = "1184--90",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - Extent of lymph node dissection and recurrence-free survival after radical cystectomy

T2 - a meta-analysis

AU - Mandel, Philipp

AU - Tilki, Derya

AU - Eslick, Guy D

N1 - Copyright © 2014 Elsevier Inc. All rights reserved.

PY - 2014/11

Y1 - 2014/11

N2 - INTRODUCTION: Lymph node dissection (LND) at the time of radical cystectomy (RC) is the standard of care in the treatment of muscle-invasive bladder cancer. However, no final consensus about its optimal extent has been reached.METHODS: We conducted a meta-analysis to determine the effect of the extent of LND on 5-year recurrence-free survival and its complication rates in patients undergoing RC. A systematic search of MEDLINE, PubMed, and EMBASE has been performed. All studies published until June 2013 and providing information on 5-year recurrence-free survival were included in the analysis.RESULTS: We analyzed the recurrence-free survival data of 11 studies on standard or extended LND or both in patients undergoing RC. The extended (above the bifurcation of iliac vessels) LND showed a significant trend toward a higher proportion of lymph node-positive patients (odds ratio = 1.39; 95% CI: 0.96-2.00; P = 0.08). Including all studies that compare extended with standard LND, the overall odds ratio for the 5-year recurrence-free survival is 1.63 (95% CI: 1.28-2.07, P<0.001), showing a strong and statistical significant survival benefit for the group of patients who underwent extended LND. Moreover, the weighted average 5-year recurrence-free survival rate of all existing studies on standard LND is significantly different from the ones reporting extended LND rates. No differences in perioperative mortality or complication rates were reported.CONCLUSION: The present meta-analysis provides evidence to the positive effect of extended LND on recurrence-free survival and its diagnostic benefit in patients undergoing RC. Patients who underwent extended LND did not suffer from higher complication rates or perioperative mortality.

AB - INTRODUCTION: Lymph node dissection (LND) at the time of radical cystectomy (RC) is the standard of care in the treatment of muscle-invasive bladder cancer. However, no final consensus about its optimal extent has been reached.METHODS: We conducted a meta-analysis to determine the effect of the extent of LND on 5-year recurrence-free survival and its complication rates in patients undergoing RC. A systematic search of MEDLINE, PubMed, and EMBASE has been performed. All studies published until June 2013 and providing information on 5-year recurrence-free survival were included in the analysis.RESULTS: We analyzed the recurrence-free survival data of 11 studies on standard or extended LND or both in patients undergoing RC. The extended (above the bifurcation of iliac vessels) LND showed a significant trend toward a higher proportion of lymph node-positive patients (odds ratio = 1.39; 95% CI: 0.96-2.00; P = 0.08). Including all studies that compare extended with standard LND, the overall odds ratio for the 5-year recurrence-free survival is 1.63 (95% CI: 1.28-2.07, P<0.001), showing a strong and statistical significant survival benefit for the group of patients who underwent extended LND. Moreover, the weighted average 5-year recurrence-free survival rate of all existing studies on standard LND is significantly different from the ones reporting extended LND rates. No differences in perioperative mortality or complication rates were reported.CONCLUSION: The present meta-analysis provides evidence to the positive effect of extended LND on recurrence-free survival and its diagnostic benefit in patients undergoing RC. Patients who underwent extended LND did not suffer from higher complication rates or perioperative mortality.

KW - Cystectomy

KW - Disease-Free Survival

KW - Humans

KW - Lymph Node Excision

KW - Lymph Nodes

KW - Prognosis

KW - Treatment Outcome

KW - Urinary Bladder Neoplasms

KW - Journal Article

KW - Meta-Analysis

U2 - 10.1016/j.urolonc.2014.01.017

DO - 10.1016/j.urolonc.2014.01.017

M3 - SCORING: Journal article

C2 - 25027683

VL - 32

SP - 1184

EP - 1190

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 8

ER -